Affordable Access

Myoclonus associated with lorazepam therapy in very-low-birth-weight infants.

Authors
  • Lee, D S
  • Wong, H A
  • Knoppert, D C
Type
Published Article
Journal
Biology of the neonate
Publication Date
Jan 01, 1994
Volume
66
Issue
6
Pages
311–315
Identifiers
PMID: 7727612
Source
Medline
License
Unknown

Abstract

Lorazepam is being used with increasing frequency as a sedative in the newborn and the young infant. Concern has been raised with regard to the safety of lorazepam in this age group, especially in very-low-birth-weight (VLBW; < 1,500 g) infants. Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of lorazepam. The potential neurotoxic effects of the drug (and its vehicle) in this population are discussed. Injectable lorazepam should be used with caution in VLBW infants.

Report this publication

Statistics

Seen <100 times